Alfred Sandrock Sells 10,885 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 10,885 shares of the company’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the sale, the chief executive officer now directly owns 430,931 shares in the company, valued at $1,478,093.33. This trade represents a 2.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Voyager Therapeutics Trading Down 0.6 %

Voyager Therapeutics stock opened at $3.09 on Friday. The firm has a market capitalization of $170.59 million, a price-to-earnings ratio of 4.35 and a beta of 1.02. The firm’s fifty day moving average price is $4.30 and its two-hundred day moving average price is $5.54. Voyager Therapeutics, Inc. has a 1-year low of $2.95 and a 1-year high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The business had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the business posted $1.25 EPS. On average, research analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on VYGR. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, March 13th. Canaccord Genuity Group reduced their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $13.97.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after acquiring an additional 6,740 shares in the last quarter. FMR LLC lifted its position in shares of Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after purchasing an additional 19,622 shares in the last quarter. Barclays PLC lifted its position in shares of Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after purchasing an additional 37,398 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Voyager Therapeutics by 23.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock worth $223,000 after purchasing an additional 7,573 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Voyager Therapeutics by 3.4% in the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock worth $405,000 after purchasing an additional 2,354 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.